5366

    543329

    WINDLAS

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    WINDLAS BIOTECH LIMITED Share Price Today

    WINDLAS BIOTECH LIMITED is currently trading at ₹839.65, down by ₹43.19 from the previous close. The stock touched an intraday high of ₹894.50 and a low of ₹820.50 during the latest trading session. Over the past one year, WINDLAS BIOTECH LIMITED has delivered a loss of 4.23%, while the stock has gained 3.38% in the last one month.

    WINDLAS BIOTECH LIMITED performance

    Today’s low Today’s high
    ₹ 820.50 ₹ 894.50
    ₹ 839.65
    52 week low 52 week high
    ₹ 697.40 ₹ 1097.90
    ₹ 839.65
    Open Price ₹ 882.85
    Prev. Close ₹ 882.85
    Volume (Shares) 114664.00
    Total traded value ₹ 962.77
    Upper Circuit ₹ 1059.40
    Lower Circuit ₹ 706.30
    info

    Investment Returns

    Over 1 Month 3.38% Over 3 Months 3.31% Over 6 Months 1.31% Over 1 Year -4.23%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    WINDLAS BIOTECH LIMITED fundamentals


    • Market cap (Cr) 1,732.70
    • P/E Ratio (TTM) 27.45
    • Beta 0.81
    • Book Value / share 281.34
    • Return on equity 12.23%
    • EPS (TTM) 32.19
    • Dividend yield 0.71%
    • Net profit/quarter (Cr) 16.02
    info icon alternate text
    • Market cap (Cr) 1,741.70
    • P/E Ratio (TTM) 27.45
    • Beta 0.73
    • Book Value / share 281.34
    • Return on equity 12.23%
    • EPS (TTM) 32.19
    • Dividend yield 0.71%
    • Net profit/quarter (Cr) 16.02
    info icon alternate text

    WINDLAS BIOTECH LIMITED Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 238.50
    Operating Expense 222.73
    Net Profit 16.02
    Net Profit Margin (%) 6.71
    Earnings Per Share (EPS) 7.60
    EBITDA 29.64
    Effective Tax Rate (%) 20.58
    Particulars DEC 2025 (Values in Cr)
    Revenue 233.10
    Operating Expense 217.70
    Net Profit 14.95
    Net Profit Margin (%) 6.41
    Earnings Per Share (EPS) 7.09
    EBITDA 28.90
    Effective Tax Rate (%) 24.94
    Particulars SEP 2025 (Values in Cr)
    Revenue 222.40
    Operating Expense 202.46
    Net Profit 17.80
    Net Profit Margin (%) 8.00
    Earnings Per Share (EPS) 8.48
    EBITDA 32.21
    Effective Tax Rate (%) 24.54
    Particulars JUN 2025 (Values in Cr)
    Revenue 210.09
    Operating Expense 192.07
    Net Profit 17.67
    Net Profit Margin (%) 8.41
    Earnings Per Share (EPS) 8.43
    EBITDA 31.77
    Effective Tax Rate (%) 24.03
    Particulars MAR 2025 (Values in Cr)
    Revenue 202.71
    Operating Expense 186.82
    Net Profit 16.29
    Net Profit Margin (%) 8.03
    Earnings Per Share (EPS) 7.77
    EBITDA 30.49
    Effective Tax Rate (%) 21.79
    Particulars MAR 2026 (Values in Cr)
    Revenue 904.09
    Operating Expense 834.97
    Net Profit 66.44
    Net Profit Margin (%) 7.34
    Earnings Per Share (EPS) 31.59
    EBITDA 122.50
    Effective Tax Rate (%) 23.58
    Particulars MAR 2025 (Values in Cr)
    Revenue 759.88
    Operating Expense 698.13
    Net Profit 60.65
    Net Profit Margin (%) 7.98
    Earnings Per Share (EPS) 29.03
    EBITDA 111.75
    Effective Tax Rate (%) 23.61
    Particulars MAR 2024 (Values in Cr)
    Revenue 630.96
    Operating Expense 567.40
    Net Profit 58.14
    Net Profit Margin (%) 9.21
    Earnings Per Share (EPS) 27.95
    EBITDA 91.55
    Effective Tax Rate (%) 24.51
    Particulars MAR 2023 (Values in Cr)
    Revenue 513.08
    Operating Expense 466.00
    Net Profit 42.64
    Net Profit Margin (%) 8.31
    Earnings Per Share (EPS) 19.71
    EBITDA 70.21
    Effective Tax Rate (%) 25.25
    Particulars MAR 2022 (Values in Cr)
    Revenue 465.93
    Operating Expense 426.60
    Net Profit 38.56
    Net Profit Margin (%) 8.27
    Earnings Per Share (EPS) 18.81
    EBITDA 59.61
    Effective Tax Rate (%) 16.24
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 275.20
    ROE % 12.23
    ROCE % 15.82
    Total Debt to Total Equity 0.06
    EBITDA Margin 13.56
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 241.30
    ROE % 12.76
    ROCE % 16.87
    Total Debt to Total Equity 0.04
    EBITDA Margin 14.75
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 216.34
    ROE % 13.66
    ROCE % 18.07
    Total Debt to Total Equity 0.01
    EBITDA Margin 14.53
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 192.24
    ROE % 10.70
    ROCE % 14.23
    Total Debt to Total Equity 0.01
    EBITDA Margin 13.68
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 181.14
    ROE % 12.83
    ROCE % 14.77
    Total Debt to Total Equity 0.07
    EBITDA Margin 12.69
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 275.20
    ROE % 12.23
    ROCE % 15.81
    Total Debt to Total Equity 0.06
    EBITDA Margin 13.55
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 241.31
    ROE % 12.69
    ROCE % 16.79
    Total Debt to Total Equity 0.04
    EBITDA Margin 14.71
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 216.51
    ROE % 13.63
    ROCE % 18.03
    Total Debt to Total Equity 0.01
    EBITDA Margin 14.51
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 192.42
    ROE % 10.69
    ROCE % 14.22
    Total Debt to Total Equity 0.01
    EBITDA Margin 13.68
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 181.30
    ROE % 12.98
    ROCE % 14.91
    Total Debt to Total Equity 0.07
    EBITDA Margin 12.79
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1.81
    Total Assets 907.34
    Total Liabilities 907.34
    Total Equity 580.83
    Share Outstanding 2
    Price to Book Ratio 2.68
    Return on Assets (%) 7.32
    Return on Capital (%) 10.88
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 15.92
    Total Assets 760.45
    Total Liabilities 760.45
    Total Equity 505.77
    Share Outstanding 2
    Price to Book Ratio 4.31
    Return on Assets (%) 8.02
    Return on Capital (%) 11.45
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 30.94
    Total Assets 626.20
    Total Liabilities 626.20
    Total Equity 449.93
    Share Outstanding 2
    Price to Book Ratio 2.37
    Return on Assets (%) 9.29
    Return on Capital (%) 12.93
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 25.45
    Total Assets 528.97
    Total Liabilities 528.97
    Total Equity 402.27
    Share Outstanding 2
    Price to Book Ratio 1.17
    Return on Assets (%) 8.05
    Return on Capital (%) 10.58
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 113.82
    Total Assets 491.01
    Total Liabilities 491.01
    Total Equity 394.77
    Share Outstanding 2
    Price to Book Ratio 1.16
    Return on Assets (%) 7.75
    Return on Capital (%) 9.5
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1.80
    Total Assets 907.33
    Total Liabilities 907.33
    Total Equity 580.83
    Share Outstanding 2
    Price to Book Ratio 2.68
    Return on Assets (%) 7.32
    Return on Capital (%) 10.88
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 15.92
    Total Assets 760.44
    Total Liabilities 760.44
    Total Equity 505.78
    Share Outstanding 2
    Price to Book Ratio 4.31
    Return on Assets (%) 7.97
    Return on Capital (%) 11.38
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 30.89
    Total Assets 626.15
    Total Liabilities 626.15
    Total Equity 450.29
    Share Outstanding 2
    Price to Book Ratio 2.37
    Return on Assets (%) 9.28
    Return on Capital (%) 12.91
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 25.45
    Total Assets 529.00
    Total Liabilities 529.00
    Total Equity 402.66
    Share Outstanding 2
    Price to Book Ratio 1.17
    Return on Assets (%) 8.06
    Return on Capital (%) 10.58
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 113.80
    Total Assets 491.02
    Total Liabilities 491.02
    Total Equity 395.12
    Share Outstanding 2
    Price to Book Ratio 1.16
    Return on Assets (%) 7.85
    Return on Capital (%) 9.61
    Particulars MAR 2026 (Values in Cr)
    Net Income 86.97
    Cash from Operations 120.08
    Cash from Investing -91.79
    Cash from Financing -13.03
    Net change in Cash 0.11
    Free Cash Flow 187.75
    Particulars MAR 2025 (Values in Cr)
    Net Income 79.75
    Cash from Operations 89.07
    Cash from Investing -74.06
    Cash from Financing 1.01
    Net change in Cash -4.86
    Free Cash Flow 141.26
    Particulars MAR 2024 (Values in Cr)
    Net Income 77.09
    Cash from Operations 127.60
    Cash from Investing -92.06
    Cash from Financing -15.29
    Net change in Cash 1.60
    Free Cash Flow 165.29
    Particulars MAR 2023 (Values in Cr)
    Net Income 57.03
    Cash from Operations 70.68
    Cash from Investing -14.11
    Cash from Financing -43.73
    Net change in Cash 3.11
    Free Cash Flow 141.57
    Particulars MAR 2022 (Values in Cr)
    Net Income 45.56
    Cash from Operations 18.01
    Cash from Investing -154.57
    Cash from Financing 130.08
    Net change in Cash -15.36
    Free Cash Flow 32.81
    Particulars MAR 2026 (Values in Cr)
    Net Income 86.93
    Cash from Operations 120.05
    Cash from Investing -91.79
    Cash from Financing -13.03
    Net change in Cash 0.10
    Free Cash Flow 187.71
    Particulars MAR 2025 (Values in Cr)
    Net Income 79.39
    Cash from Operations 89.09
    Cash from Investing -74.06
    Cash from Financing 1.01
    Net change in Cash -4.81
    Free Cash Flow 141.29
    Particulars MAR 2024 (Values in Cr)
    Net Income 77.02
    Cash from Operations 127.53
    Cash from Investing -92.06
    Cash from Financing -15.28
    Net change in Cash 1.55
    Free Cash Flow 165.21
    Particulars MAR 2023 (Values in Cr)
    Net Income 57.05
    Cash from Operations 70.69
    Cash from Investing -14.11
    Cash from Financing -43.73
    Net change in Cash 3.13
    Free Cash Flow 141.58
    Particulars MAR 2022 (Values in Cr)
    Net Income 46.03
    Cash from Operations 17.87
    Cash from Investing -154.30
    Cash from Financing 130.08
    Net change in Cash -15.22
    Free Cash Flow 32.67
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 46.63 19.35 2.25 357.34 23.12 47.39
    BLISS GVS PHARMA LTD. 477.10 38.41 4.24 5068.90 118.35 552.90
    CIPLA LTD. 1472.00 33.23 3.45 118914.83 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 559.55 26.17 4.05 1646.81 256.40 568.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 46.63 32.61 6.00 357.34 23.12 47.39
    AMRUTANJAN HEALTH CARE LTD. 522.95 23.44 4.08 1511.88 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8188.15 107.01 23.45 20470.38 7630.00 9850.00
    BLISS GVS PHARMA LTD. 477.10 51.63 4.38 5068.90 118.35 552.90

    WINDLAS BIOTECH LIMITED shareholding pattern

    Holding
    24.8%
    63.31%
    2.04%
    9.84%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    WINDLAS BIOTECH LIMITED Technicals Summary

    839.65 -4.89 redarrow
    red-green-graph indicator
    13 Bearish
    3 Bullish
    • 5 Days 870.60
    • 26 Days 857.30
    • 10 Days 865.80
    • 50 Days 846.80
    • 12 Days 864.50
    • 100 Days 834.70
    • 20 Days 860.30
    • 200 Days 840.60
    877.70 PIVOT
    First Support 866.95 First Resistance 893.60 Second Support 851.05 Second Resistance 904.35 Third Support 840.30 Third Resistance 920.25
    RSI 61.64 ADX 16.71 MACD 7.24 Williams % R -19.08 Commodity Channel Index (CCI) 147.35
    Date 2026-08-07 Week 16459.00 Same Day 30989.00 Month 22128.00
    1 Year 0.82 3 Year 0.94
    Over 1 Month
    3.38% down
    Over 1 Year
    -4.23% down
    Over 3 Months
    3.31% down
    Over 3 Years
    40.53% down
    Over 6 Months
    1.31% down
    Over 5 Years
    16.74% down

    WINDLAS BIOTECH LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    16 Jul 2026 6.3 Final 16 Jul 2026 Equity shares
    21 Jul 2025 5.8 Final 21 Jul 2025 Equity shares
    17 Sep 2024 5.5 Final 17 Sep 2024 Equity shares
    05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
    09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    16 Jul 2026 6.3 Final 16 Jul 2026 Equity shares
    21 Jul 2025 5.8 Final 21 Jul 2025 Equity shares
    17 Sep 2024 5.5 Final 17 Sep 2024 Equity shares
    05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
    09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Windlas Biotech Ltd?

    Answer Field

    Windlas Biotech Ltd share price is for NSE ₹ 839.65 & for BSE ₹ 828.00 as on Aug 10 2026 03:30 PM.

    What is the Market Cap of Windlas Biotech Ltd Share?

    Answer Field

    The market cap of Windlas Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Aug 10 2026 03:30 PM.

    What is the 52 Week High and Low of Windlas Biotech Ltd?

    Answer Field

    The 52 Week High and Low of Windlas Biotech Ltd for NSE is ₹ 1,097.90 and ₹ 697.40 and for BSE is ₹ 1,095.00 and ₹ 699.35.

    What is 1 year return for Windlas Biotech Ltd?

    Answer Field

    The 1 year returns on the stock has been -4.23%.

    What is the P/E Ratio of Windlas Biotech Ltd Share?

    Answer Field

    As on Aug 10 2026 03:30 PM the price-to-earnings (PE) ratio for Windlas Biotech Ltd share is 27.45.

    What is the PB ratio of Windlas Biotech Ltd Share?

    Answer Field

    As on Aug 10 2026 03:30 PM, the price-to-book (PB) ratio for Windlas Biotech Ltd share is 281.34.

    How to Buy Windlas Biotech Ltd Share?

    Answer Field

    You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Windlas Biotech Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Windlas Biotech Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Windlas Biotech Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |